Beneficial effects of melatonin in cardiovascular disease

Annals of Medicine

Volumn 42, Issue 4, 2010, Pages 276-285

  Reiter, Russel J ^a   Tan, Dun Xian ^a   Paredes, Sergio D ^a   Fuentes Broto, Lorena ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Anti oxidant; Cardiac hypertrophy; Cardiovascular system; Free radical; Heart attack; Heart disease; Hypertension; Ischemia reperfusion; Melatonin

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; ALPHA TOCOPHEROL; CYCLOSPORIN A; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MELATONIN; PLACEBO; ANTIOXIDANT; CARDIOTONIC AGENT;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; ESSENTIAL HYPERTENSION; EVENING DOSAGE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REPERFUSION INJURY; ANIMAL; DRUG EFFECT; DRUG TOXICITY; HOSPITALIZATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RODENT;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DRUG TOXICITY; HUMANS; MELATONIN; OXIDATIVE STRESS; RODENTIA; SEVERITY OF ILLNESS INDEX;

EID: 77952131530     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890903485748     Document Type: Article

References (84)

1. Reiter RJ, Tan DX, Manchester LC, Terron MP, Flores LJ, Koppisetti S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci. 2007;52:11-28.
2. Dubocovich M, Markowska M. Functional MT1 and MT2 mel atonin receptors in mammals. Endocrine. 2005;27:101-111
3. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27:189-200.
4. Vella F, Ferry G, Delagrange P, Boutin JA. Quinone redu-ctase 2: an enzyme of surprises and mysteries. Biochem Pharmacol. 2005;71:1-12.
5. Tan DX, Manchester LC, Terron MP, Flores LJ, Tamura H, Reiter RJ. Melatonin as a naturally occurring co-substrate of quinone reductase-2, a putative MT3 melatonin membrane receptor: hypothesis and signifi cance. J Pineal Res. 2007; 43:317-320
6. Acuna-Castroviejo D, Reiter RJ, Menendez-Pelaez A, Pablos MI, Burgos A. Characterization of high-affi nity melatonin binding sites in purifi ed cell nuclei of rat liver. J Pineal Res. 1994;16:100-112
7. Benitez-King G. Melatonin as a cytoskeleton modulator: implications for cell physiology and disease. J Pineal Res. 2006;40:1-9.
8. Kennaway DJ, Wright H. Melatonin and circadian rhythms. Curr Topics Med Chem. 2002;2:199-209.
9. Slominski A, Fischer TW, Zmijewski MA, Wortsman J, Semak I, Zbytek B, et al. On the role of melatonin in skin physiology and pathology. Endocrine. 2005;27:137-147
10. Blask DE, Brainaid GC, Dauchy RT. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenographs in nude rats. Cancer Res. 2005;65:11174-11184
11. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjunct therapy. J Pineal Res. 2006;41:297-305.
12. Rögelsperger O, Ekmekcioglu L, Jäger W, Klimpfi nger M, Königsberg R, Krenbek D, et al. Coexpression of the mela-tonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009;46:422-432
13. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine J. 1993;1:57-60.
14. Escames G, Acuna-Castroviejo D, Lopez LC, Maldonado MD, Sanchez-Hidalgo M, Leon J, et al. The pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J Pharm Pharmacol. 2006;58:1153-1165
15. Acuna-Castroviejo D, Escames G, Carazo A, Leon J, Khaldy H, Reiter RJ. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr Topics Med Chem. 2002;2:133-152
16. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res. 2007;34:1-10.
17. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species. J Pineal Res. 2007;42:28-42.
18. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res. 2008;45: 235-246
19. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res. 2009;47: 109-126
20. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005;27:179-188
21. Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res. 2007;42:22-27
22. Fischer TW, Slominski A, Tobin DJ, Paus R. Melatonin and the hair follicle. J Pineal Res. 2008;44:1-15.
23. Koppisetti S, Jenigiri B, Terron MP, Tengattini S, Tamura H, Flores LJ, et al. Reactive oxygen species and the hypomotil-ity of the gall bladder as targets for the treatment of gallstones with melatonin: a renew. Dig Dis Sci. 2008;2592-2603
24. Reiter RJ, Korkmaz A. Clinical aspects of melatonin. Saudi Med J. 2008;29:1537-1547
25. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre-and postnatal period and the clinical utility of melatonin. J Pineal Res. 2009;46: 128-139
26. Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sargino N, et al. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2009;92:328-343
27. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin, an established antioxidant worthy of use in clinical trials. Mol Med. 2009;15:43-50.
28. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Rev. 1991;12: 151-180
29. Carpizo R, Martinez A, Mediavilla, D, Gonzalez M, Abad A, Sanchez-Barcelo E. Smith-Magenis syndrome: a case report of improved sleep after treatment with beta-1-adrenergic antagonists and melatonin. J Pediatr. 2006;149:409-411
30. Birau N, Petersen U, Meyer C, Gottschallt J. Hypotensive effect of melatonin in essential hypertension. IRCS Med Sci. 1981;9:906.
31. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007;42:319-322
32. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hyperten. 2009;27(Suppl 6):517-520
33. Zamboni A, Zamboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sci. 1967;6:2327-2331
34. Holmes SW, Sugden D. The effect of melatonin on pinealectomy-induced hypertension in rats. Br J Pharmacol. 1976;56:360-361
35. Sack RL, Lewy AJ, Erb DZ, Vollmer WM, Singer CM. Human melatonin production decreases with age. J Pineal Res. 1986;3:379-388
36. Reiter RJ. The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp Gerontol. 1995;9:199-212.
37. Kawashima K, Miwa Y, Fujimoto K, Oohata H, Nishino H, Koike H. Antihypertensive action of melatonin in the spontaneously hypertensive rat. Clin Exp Hyperten A. 1987;6:1517-1528
38. Nava M, Quiroz Y, Vaziri W, Rodriguez-Iturbe B. Melatonin reduces renal interstitial infl ammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2003;284:F477-54.
39. O'Brien E, Scheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988;2:397.
40. Mansoor GA. Sleep actigraphy in hypertensive patients with the 'non-dipper' blood pressure profi le. J Human Hyperten. 2002;16:237-242
41. Jonas, M, Garfi nkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003;12:19-24.
42. Scheer FAJL, Van Montfrans GA, van Somersen EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43:192-197
43. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315
44. Staessen JA, Thijs L, Fagard P, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539-546
45. Scheer FA, Czeisler CA. Melatonin, sleep and circadian rhythms. Sleep Med Rev. 2005;9:5-9.
46. Scheer FA, Cajochen C, Turek FW, Czeisler CA. Melatonin in the regulation of sleep and circadian rhythms. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 4th Edition, 2005. Philadelphia: WB Saunders. p. 395-404.
47. Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, Volpe A. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hyperten. 2005;18:1614-1618
48. Textor SC, Wilcox CS. Renal artery stenosis: a com mon treatable cause of renal failure. Annu Rev Med. 2001;52: 421-442
49. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin-II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593
50. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009; 44:175-200.
51. Ersahin M, Sehirli O, Toklu HZ, Suleymanoglu S, Emekli-Aturfan E, Yarat A, et al. Melatonin improves cardiovascular function and ameliorates renal, cardiac and cerebral damage in rats with renovascular hypertension. J Pineal Res. 2009;47:97-106.
52. Xia CH, Shan CH, Xin L, Wang YR, Ding CN, Wang J, et al. Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol. 2008;35:1258-1264
53. Hilton SM, Spyer KM. Participation of the anterior hypothala-mus in the baroreceptor refl ex. J Physiol. 1971;218:271-293
54. Wu YH, Zhou JN, Balesar R, Unmehopa U, Bao A, Jockers R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: co-localization of MT1 with vasopressin, oxytocin and corticotropin-releasing hormone. J Comp Neurol. 2006;499: 897-910.
55. Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. Expression of the MT1 mela-tonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21:85-91.
56. Reiter RJ. Melatonin: lowering the high price of free radicals. News Physiol Sci. 2000;15:246-250
57. Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci. 2008;65:2001-2018
58. Reiter RJ, Ta n DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 2003;58:10-19
59. Dobsak P, Siegelova J, Eicher JC, Jancik J, Svacinova H, Vasku J, et al. Melatonin protects against ischemia-reperfusion injury and inhibits apoptosis in isolated working rat heart. Pathophysiology. 2003;9:179-187
60. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000;109:315-323
61. Petrosillo G, Di Venosa N, Pistolese M, Casanova G, Tiravanti E, Colantuono G, et al. Protective effect of mela-tonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J. 2006;20:269-276
62. Petrosillo FM, Colantuono G, Moro N, Ruggiero FM, Tiravanti E, Di Venosa N, et al. Melatonin protects against heart ischemia/reperfusion injury by inhibiting permeability transition pore opening. Am J Physiol Heart Circ Physiol. 2009;297:H1487-93.
63. Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, et al. Melatonin protects against common deletion of mitochon-drial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res. 2007;43:389-403.
64. Reiter RJ, Paredes SD, Korkmaz A, Jou MJ, Tan DX. Mela-tonin combats molecular terrorism at the mitochondrial level. Interdisc Toxicol. 2008;1:139-148
65. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;4:155-225.
66. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007:27:15-26.
67. Landmesser U, Harrison DG. Oxidant stress as marker for cardiovascular events: OX marks the spot. Circulation. 2001; 104:2638-2640
68. Witztum JL, Steinberg D. The oxidative modifi cation hypothesis of atherosclerosis: does it hold for humans. Trends Cadiovasc Med. 2001;11:93-102.
69. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifi cations of low density lipopro-tein that increase atherogenicity. N Engl J Med. 1989;320: 915-924
70. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC, Reiter RJ. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res. 2008;44:65-69
71. Piere C, Marra M, Gaspar R, Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apol-ipoprotein derivatization. Biochem Biophys Res Commun. 1996;222:256-260
72. Kelly MR, Loo G. Melatonin inhibits oxidative modifi cation of human low-density lipoprotein. J Pineal Res. 1997;22: 203-209
73. Seegar H, Mueck AO, Lippert TH. Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein. Br J Clin Pharmacol. 1997;44:283-284
74. Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, Fabrian F, Garcia-Perganeda A, et al. Serum cholesterol and lipid per-oxidation are decreased by melatonin in diet-induced hyper-cholesterolemic rats. J Pineal Res. 2000;28:150-155
75. Abyja PM, Liebmann P, Hayn M, Schauenstein K, Esterbauer H. Antioxidant role of melatonin in lipid peroxidation of human LDL. FEBS Lett. 1997;413: 289-293
76. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J Pineal Res. 2001;31:281-288
77. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer-Hita J, Vargas M, Reiter RJ. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis. 2003;180:101-105
78. Tamura H, Nakamura Y, Narimatsu A, Yamagata Y, Takasaki A, Reiter RJ, et al. Melatonin treatment in peri-and postmenopausal women elevates serum high density lipopro-tein cholesterol levels without infl uencing total cholesterol levels. J Pineal Res. 2008;45:101-105
79. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decomposition in rats with chronic aortic banding. Circ Res. 1993;73:184-192
80. Ghosh G, De K, Maity S, Bandyopadhyay D, Bhattacharya S, Reiter RJ, et al. Melatonin protects against oxidative damage and restores expression of GLUT4 gene in the hyperthyroid rat heart. J Pineal Res. 2007;42:71-82.
81. Friehs I, Moran AM, Stamm C, Colan SD, Takeuchi K, Cao-Danh H, et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation. 1999;100:11187-11193
82. Reiter RJ, Tan DX, Sainz RM, Mayo JC. Melatonin: reducing the toxicity and increasing the effi cacy of drugs. J Pharm Pharmacol. 2002;54:1299-1321
83. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferu-loylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. 2005;15:5-15.
84. Rezzani R, Rodella LF, Bonomini F, Tengattini S, Bianchi R, Reiter RJ. Benefi cial effects of melatonin in protecting against cyclosporine A-induced cardiotoxicity are receptor mediated. J Pineal Res. 2006;41:288-295